JP2010529195A - プロテインキナーゼの阻害剤としてのイミダゾピラジン - Google Patents
プロテインキナーゼの阻害剤としてのイミダゾピラジン Download PDFInfo
- Publication number
- JP2010529195A JP2010529195A JP2010512177A JP2010512177A JP2010529195A JP 2010529195 A JP2010529195 A JP 2010529195A JP 2010512177 A JP2010512177 A JP 2010512177A JP 2010512177 A JP2010512177 A JP 2010512177A JP 2010529195 A JP2010529195 A JP 2010529195A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- heteroaryl
- aryl
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 *c1cnc2[n]1c(*)c(*)nc2* Chemical compound *c1cnc2[n]1c(*)c(*)nc2* 0.000 description 43
- JSZSUVYDMFXYMJ-UHFFFAOYSA-N CCN(Cc1n[s]c(Nc2nc(C)c[n]3c2ncc3-c2c[nH]nc2)c1)C(C)C Chemical compound CCN(Cc1n[s]c(Nc2nc(C)c[n]3c2ncc3-c2c[nH]nc2)c1)C(C)C JSZSUVYDMFXYMJ-UHFFFAOYSA-N 0.000 description 2
- XXZBSHXQGNRAGA-UHFFFAOYSA-N Cc(nc1Nc2cc(CN(C)CCOC)n[s]2)c[n]2c1ncc2-c1c[nH]nc1 Chemical compound Cc(nc1Nc2cc(CN(C)CCOC)n[s]2)c[n]2c1ncc2-c1c[nH]nc1 XXZBSHXQGNRAGA-UHFFFAOYSA-N 0.000 description 2
- NKBNXUWNZKJYFT-UHFFFAOYSA-N Cc(nc1Nc2cc(CN(CC3)c4c3cccc4)n[s]2)c[n]2c1ncc2-c1c[nH]nc1 Chemical compound Cc(nc1Nc2cc(CN(CC3)c4c3cccc4)n[s]2)c[n]2c1ncc2-c1c[nH]nc1 NKBNXUWNZKJYFT-UHFFFAOYSA-N 0.000 description 2
- BSFDOYQVJQSYGH-UHFFFAOYSA-N C(c1n[s]c(Nc2ncc[n]3c2ncc3C2CC2)c1)N1CCCCC1 Chemical compound C(c1n[s]c(Nc2ncc[n]3c2ncc3C2CC2)c1)N1CCCCC1 BSFDOYQVJQSYGH-UHFFFAOYSA-N 0.000 description 1
- KYLIDFOVFXITQZ-UHFFFAOYSA-N CC1CN(Cc2ncc(Nc3nc(C)c[n]4c3ncc4-c3c[nH]nc3)[s]2)CCC1 Chemical compound CC1CN(Cc2ncc(Nc3nc(C)c[n]4c3ncc4-c3c[nH]nc3)[s]2)CCC1 KYLIDFOVFXITQZ-UHFFFAOYSA-N 0.000 description 1
- ODIVVGSONMDVTG-UHFFFAOYSA-N CCCC(CCOCI)Cc1n[s]c(Nc2nc(C)c[n]3c2ncc3-c2c[nH]nc2)c1 Chemical compound CCCC(CCOCI)Cc1n[s]c(Nc2nc(C)c[n]3c2ncc3-c2c[nH]nc2)c1 ODIVVGSONMDVTG-UHFFFAOYSA-N 0.000 description 1
- KVVFDOHCNNBHGA-UHFFFAOYSA-N CCCCCNC(c1c(C)cc(C)[s]1)=O Chemical compound CCCCCNC(c1c(C)cc(C)[s]1)=O KVVFDOHCNNBHGA-UHFFFAOYSA-N 0.000 description 1
- NZHOFVUGFDMAKC-UHFFFAOYSA-N CCCN(CC1CC1)Cc1ncc(Nc2nc(C)c[n]3c2ncc3-c2c[nH]nc2)[s]1 Chemical compound CCCN(CC1CC1)Cc1ncc(Nc2nc(C)c[n]3c2ncc3-c2c[nH]nc2)[s]1 NZHOFVUGFDMAKC-UHFFFAOYSA-N 0.000 description 1
- QZVBHJSGFZOODY-UHFFFAOYSA-N CCCN(Cc1n[s]c(Nc2nc(C)c[n]3c2ncc3-c2c[nH]nc2)c1)C(C)(C)CO Chemical compound CCCN(Cc1n[s]c(Nc2nc(C)c[n]3c2ncc3-c2c[nH]nc2)c1)C(C)(C)CO QZVBHJSGFZOODY-UHFFFAOYSA-N 0.000 description 1
- DJURXUIQCZTMBT-UHFFFAOYSA-N CCN(CC(C1)=NSC1Nc1nc(C)c[n]2c1ncc2-c1c[nH]nc1)C(C)(C)CO Chemical compound CCN(CC(C1)=NSC1Nc1nc(C)c[n]2c1ncc2-c1c[nH]nc1)C(C)(C)CO DJURXUIQCZTMBT-UHFFFAOYSA-N 0.000 description 1
- CRAPTZQEZUPRPB-UHFFFAOYSA-N CCN(CC)C(c1c(CN2CCCC2)cc(Nc2nc(C)c[n]3c2ncc3C2(C)C=NNC2)[s]1)=O Chemical compound CCN(CC)C(c1c(CN2CCCC2)cc(Nc2nc(C)c[n]3c2ncc3C2(C)C=NNC2)[s]1)=O CRAPTZQEZUPRPB-UHFFFAOYSA-N 0.000 description 1
- UMTSPEYWKSQTCM-UHFFFAOYSA-N CCN(CI)C(c1c(CN2CCCC2)cc(Nc2nc(C)c[n]3c2ncc3-c2c[nH]nc2)[s]1)=O Chemical compound CCN(CI)C(c1c(CN2CCCC2)cc(Nc2nc(C)c[n]3c2ncc3-c2c[nH]nc2)[s]1)=O UMTSPEYWKSQTCM-UHFFFAOYSA-N 0.000 description 1
- ZYFKWJGHCWHTCU-SSZFMOIBSA-N CCN(Cc1n[s]c(NC(C)c2ncc(C3C=NNC3)[n]2/C=C(/C)\N)c1)C1(CO)CCCC1 Chemical compound CCN(Cc1n[s]c(NC(C)c2ncc(C3C=NNC3)[n]2/C=C(/C)\N)c1)C1(CO)CCCC1 ZYFKWJGHCWHTCU-SSZFMOIBSA-N 0.000 description 1
- SKTQHWFPLXLXPV-UHFFFAOYSA-N CCN(Cc1n[s]c(Nc2nc(C)c[n]3c2ncc3-c2c[nH]nc2)c1)C1(CO)CCCCC1 Chemical compound CCN(Cc1n[s]c(Nc2nc(C)c[n]3c2ncc3-c2c[nH]nc2)c1)C1(CO)CCCCC1 SKTQHWFPLXLXPV-UHFFFAOYSA-N 0.000 description 1
- DFKFBFOFIXOWIU-UHFFFAOYSA-N CCN(Cc1n[s]c(Nc2nc(C)c[n]3c2ncc3-c2c[nH]nc2)c1)Cc1ccncc1 Chemical compound CCN(Cc1n[s]c(Nc2nc(C)c[n]3c2ncc3-c2c[nH]nc2)c1)Cc1ccncc1 DFKFBFOFIXOWIU-UHFFFAOYSA-N 0.000 description 1
- IQHHNYYIIRAGJF-QNSVNVJESA-N CCOC(C1CC[C@H](Cc2n[s]c(Nc3nc(C)c[n]4c3ncc4-c3c[nH]nc3)c2)CCCC1)=O Chemical compound CCOC(C1CC[C@H](Cc2n[s]c(Nc3nc(C)c[n]4c3ncc4-c3c[nH]nc3)c2)CCCC1)=O IQHHNYYIIRAGJF-QNSVNVJESA-N 0.000 description 1
- XMVZZEFBHYHVOH-GOSISDBHSA-N CCOC[C@@H]1N(Cc2n[s]c(Nc3nc(C)c[n]4c3ncc4-c3c[nH]nc3)c2)CCCC1 Chemical compound CCOC[C@@H]1N(Cc2n[s]c(Nc3nc(C)c[n]4c3ncc4-c3c[nH]nc3)c2)CCCC1 XMVZZEFBHYHVOH-GOSISDBHSA-N 0.000 description 1
- OWLUPWJGLMOPGR-OAQYLSRUSA-N C[C@@]1(CO)N(Cc2n[s]c(Nc3nc(C)c[n]4c3ncc4-c3c[nH]nc3)c2)CCCC1 Chemical compound C[C@@]1(CO)N(Cc2n[s]c(Nc3nc(C)c[n]4c3ncc4-c3c[nH]nc3)c2)CCCC1 OWLUPWJGLMOPGR-OAQYLSRUSA-N 0.000 description 1
- MDERIMDTONVDFE-QFIPXVFZSA-N C[C@@]1(COC)CN(Cc2n[s]c(Nc3nc(C)c[n]4c3ncc4-c3c[nH]nc3)c2)CCC1 Chemical compound C[C@@]1(COC)CN(Cc2n[s]c(Nc3nc(C)c[n]4c3ncc4-c3c[nH]nc3)c2)CCC1 MDERIMDTONVDFE-QFIPXVFZSA-N 0.000 description 1
- CTPRSLZUIGQNOM-JOCHJYFZSA-N C[C@@]1(COC)N(Cc2n[s]c(Nc3nc(C)c[n]4c3ncc4-c3c[nH]nc3)c2)CCCC1 Chemical compound C[C@@]1(COC)N(Cc2n[s]c(Nc3nc(C)c[n]4c3ncc4-c3c[nH]nc3)c2)CCCC1 CTPRSLZUIGQNOM-JOCHJYFZSA-N 0.000 description 1
- OWLUPWJGLMOPGR-NRFANRHFSA-N C[C@]1(CO)N(Cc2n[s]c(Nc3nc(C)c[n]4c3ncc4-c3c[nH]nc3)c2)CCCC1 Chemical compound C[C@]1(CO)N(Cc2n[s]c(Nc3nc(C)c[n]4c3ncc4-c3c[nH]nc3)c2)CCCC1 OWLUPWJGLMOPGR-NRFANRHFSA-N 0.000 description 1
- CTPRSLZUIGQNOM-QFIPXVFZSA-N C[C@]1(COC)N(Cc2n[s]c(Nc3nc(C)c[n]4c3ncc4-c3c[nH]nc3)c2)CCCC1 Chemical compound C[C@]1(COC)N(Cc2n[s]c(Nc3nc(C)c[n]4c3ncc4-c3c[nH]nc3)c2)CCCC1 CTPRSLZUIGQNOM-QFIPXVFZSA-N 0.000 description 1
- XWEGUCZIOBVCAH-UHFFFAOYSA-N C[Si+](C)(C)CCOC[n]1ncc(-c2cnc(c(S(C)(=O)=O)n3)[n]2cc3Br)c1 Chemical compound C[Si+](C)(C)CCOC[n]1ncc(-c2cnc(c(S(C)(=O)=O)n3)[n]2cc3Br)c1 XWEGUCZIOBVCAH-UHFFFAOYSA-N 0.000 description 1
- SADLNBVGSOJFNI-UHFFFAOYSA-N Cc(nc1NC2=CCC(CN3CCCC3)=C(C(N3CCCCC3)=O)S2)c[n]2c1ncc2C1C=NNC1 Chemical compound Cc(nc1NC2=CCC(CN3CCCC3)=C(C(N3CCCCC3)=O)S2)c[n]2c1ncc2C1C=NNC1 SADLNBVGSOJFNI-UHFFFAOYSA-N 0.000 description 1
- TVAXNQZCWGTQKA-UHFFFAOYSA-N Cc(nc1Nc2cc(CN(C(CC3)C4)C3C4S(C=C3)C=C3c3cnc4[n]3cc(C)nc4Nc3cc(CO)n[s]3)n[s]2)c[n]2c1ncc2-c1c[nH]nc1 Chemical compound Cc(nc1Nc2cc(CN(C(CC3)C4)C3C4S(C=C3)C=C3c3cnc4[n]3cc(C)nc4Nc3cc(CO)n[s]3)n[s]2)c[n]2c1ncc2-c1c[nH]nc1 TVAXNQZCWGTQKA-UHFFFAOYSA-N 0.000 description 1
- RDRZNFWKWSUAFW-UHFFFAOYSA-N Cc(nc1Nc2cc(CN(CCC3)CC3(F)F)n[s]2)c[n]2c1ncc2-c1c[nH]c(I)c1 Chemical compound Cc(nc1Nc2cc(CN(CCC3)CC3(F)F)n[s]2)c[n]2c1ncc2-c1c[nH]c(I)c1 RDRZNFWKWSUAFW-UHFFFAOYSA-N 0.000 description 1
- ZTFMMIKRKMQOSS-UHFFFAOYSA-N Cc(nc1Nc2cc(CN)n[s]2)c[n]2c1ncc2-c1c[nH]nc1 Chemical compound Cc(nc1Nc2cc(CN)n[s]2)c[n]2c1ncc2-c1c[nH]nc1 ZTFMMIKRKMQOSS-UHFFFAOYSA-N 0.000 description 1
- LSTQMKYKOLASCW-UHFFFAOYSA-N Cc(nc1Nc2cc(CN3C4CCC3CC4)n[s]2)c[n]2c1ncc2-c1c[nH]nc1 Chemical compound Cc(nc1Nc2cc(CN3C4CCC3CC4)n[s]2)c[n]2c1ncc2-c1c[nH]nc1 LSTQMKYKOLASCW-UHFFFAOYSA-N 0.000 description 1
- GQTPBKOMPIOHAQ-UHFFFAOYSA-N Cc(nc1Nc2cc(CN3CCOCC3)n[s]2)c[n]2c1ncc2-c1c[nH]nc1 Chemical compound Cc(nc1Nc2cc(CN3CCOCC3)n[s]2)c[n]2c1ncc2-c1c[nH]nc1 GQTPBKOMPIOHAQ-UHFFFAOYSA-N 0.000 description 1
- QEXFFSRORKQRQA-UHFFFAOYSA-N Cc(nc1Nc2cc(CN3Cc4ccccc4C3)n[s]2)c[n]2c1ncc2-c1c[nH]nc1 Chemical compound Cc(nc1Nc2cc(CN3Cc4ccccc4C3)n[s]2)c[n]2c1ncc2-c1c[nH]nc1 QEXFFSRORKQRQA-UHFFFAOYSA-N 0.000 description 1
- BFVXUBGCSLAWRF-UHFFFAOYSA-N Cc(nc1Nc2cc(CO)n[s]2)c[n]2c1ncc2-c1c[s]cc1 Chemical compound Cc(nc1Nc2cc(CO)n[s]2)c[n]2c1ncc2-c1c[s]cc1 BFVXUBGCSLAWRF-UHFFFAOYSA-N 0.000 description 1
- ZNVLTUOSLHBJTI-UHFFFAOYSA-N Cc1cc(CN2CCCCC2)n[s]1 Chemical compound Cc1cc(CN2CCCCC2)n[s]1 ZNVLTUOSLHBJTI-UHFFFAOYSA-N 0.000 description 1
- ZLCMZHRQFPNSFU-UHFFFAOYSA-N Cc1cc(CN2CCOCC2)c(C(N2CCSCC2)=O)[s]1 Chemical compound Cc1cc(CN2CCOCC2)c(C(N2CCSCC2)=O)[s]1 ZLCMZHRQFPNSFU-UHFFFAOYSA-N 0.000 description 1
- IIBBGEVSSATDIP-UHFFFAOYSA-N Cc1cc(CN2Cc3ccccc3CC2)n[s]1 Chemical compound Cc1cc(CN2Cc3ccccc3CC2)n[s]1 IIBBGEVSSATDIP-UHFFFAOYSA-N 0.000 description 1
- NVTAXTNNSSZOFU-UHFFFAOYSA-N Cc1cc(CO)n[s]1 Chemical compound Cc1cc(CO)n[s]1 NVTAXTNNSSZOFU-UHFFFAOYSA-N 0.000 description 1
- NRTWXBXJSGGTTE-UHFFFAOYSA-N Cc1cc(N)ccc1C(OC)=O Chemical compound Cc1cc(N)ccc1C(OC)=O NRTWXBXJSGGTTE-UHFFFAOYSA-N 0.000 description 1
- JBZFWJJJLREXJO-UHFFFAOYSA-N Cc1ccc(CN2CCOCC2)cc1 Chemical compound Cc1ccc(CN2CCOCC2)cc1 JBZFWJJJLREXJO-UHFFFAOYSA-N 0.000 description 1
- NQBVXOIFZISUFI-UHFFFAOYSA-N Cc1ccc2C3=CCc2c13 Chemical compound Cc1ccc2C3=CCc2c13 NQBVXOIFZISUFI-UHFFFAOYSA-N 0.000 description 1
- ZFUGIGVCZFPDIB-UHFFFAOYSA-N Ic1cc(CN2CCSCC2)n[s]1 Chemical compound Ic1cc(CN2CCSCC2)n[s]1 ZFUGIGVCZFPDIB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94399907P | 2007-06-14 | 2007-06-14 | |
| US98793207P | 2007-11-14 | 2007-11-14 | |
| PCT/US2008/007295 WO2008156614A2 (en) | 2007-06-14 | 2008-06-11 | Imidazopyrazines as protein kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2010529195A true JP2010529195A (ja) | 2010-08-26 |
Family
ID=40002934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010512177A Withdrawn JP2010529195A (ja) | 2007-06-14 | 2008-06-11 | プロテインキナーゼの阻害剤としてのイミダゾピラジン |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP2170892A2 (zh) |
| JP (1) | JP2010529195A (zh) |
| CN (1) | CN101772500A (zh) |
| AR (1) | AR066958A1 (zh) |
| CA (1) | CA2690557A1 (zh) |
| CL (1) | CL2008001745A1 (zh) |
| MX (1) | MX2009013729A (zh) |
| PE (1) | PE20090365A1 (zh) |
| TW (1) | TW200911811A (zh) |
| WO (1) | WO2008156614A2 (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014501496A (ja) * | 2010-10-20 | 2014-01-23 | ユニヴェルシテ ボルドー セガラン | 消化管間質腫瘍における臨床転帰のシグネチャーおよび消化管間質腫瘍の治療の方法 |
| JP2023523962A (ja) * | 2020-04-29 | 2023-06-08 | エフ． ホフマン－ラ ロシュ アーゲー | 抗菌８－フェニルアミノ－３－（ピラゾール－４－イル）イミダゾ［１，２－ａ］ピラジン誘導体 |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102428087B (zh) | 2009-04-16 | 2015-06-17 | 卡洛斯三世国家癌症研究中心基金会 | 用作激酶抑制剂的咪唑并吡嗪类化合物 |
| TW201107329A (en) * | 2009-07-30 | 2011-03-01 | Oncotherapy Science Inc | Fused imidazole derivative having ttk inhibitory action |
| EP2473041B1 (en) | 2009-09-04 | 2018-03-07 | Merck Sharp & Dohme Corp. | Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors |
| BR112012010041A2 (pt) | 2009-10-30 | 2016-05-24 | Janssen Pharmaceutica Nv | derivados de imidazo [1,2-b] piridazina e seu uso como inibidores de pde10 |
| AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
| WO2011151259A1 (en) * | 2010-06-01 | 2011-12-08 | Bayer Pharma Aktiengesellschaft | Substituted imidazopyrazines |
| WO2012052745A1 (en) | 2010-10-21 | 2012-04-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Combinations of pi3k inhibitors with a second anti -tumor agent |
| EP2444084A1 (en) | 2010-10-21 | 2012-04-25 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Use of PI3K inibitors for the treatment of obesity |
| CA2821834A1 (en) * | 2010-12-17 | 2012-06-21 | Bayer Intellectual Property Gmbh | 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| US8673905B2 (en) * | 2011-03-17 | 2014-03-18 | Hoffmann-La Roche Inc. | Imidazo pyrazines |
| CN103732589B (zh) | 2011-05-25 | 2016-03-30 | 百时美施贵宝公司 | 可用作抗细胞凋亡bcl抑制剂的取代的磺酰胺 |
| WO2013000924A1 (en) | 2011-06-27 | 2013-01-03 | Janssen Pharmaceutica Nv | 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES |
| ES2855575T3 (es) | 2012-06-26 | 2021-09-23 | Janssen Pharmaceutica Nv | Combinaciones que comprenden compuestos de 4-metil-[1,2,4]triazolo[4,3-a]quinoxalina como inhibidores de PDE2 e inhibidores de PDE10 para su uso en el tratamiento de trastornos neurológicos o metabólicos |
| EP2869822B1 (en) | 2012-07-09 | 2016-09-14 | Janssen Pharmaceutica, N.V. | Inhibitors of phosphodiesterase 10 enzyme |
| SI3466955T1 (sl) | 2014-01-13 | 2021-05-31 | Aurigene Discovery Technologies Limited | Postopek za pripravo derivatov oksazolo(4,5-B)piridina in tiazolo(4,5-B)piridina kot inhibitorjev IRAK4 za zdravljenje raka |
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| CR20160395A (es) | 2014-02-13 | 2016-12-20 | Incyte Corp | Ciclopropilaminas como inhibidores de lsd1 |
| ES2672797T3 (es) | 2014-02-13 | 2018-06-18 | Incyte Corporation | Ciclopropilaminas como inhibidores de LSD1 |
| MY183499A (en) | 2014-02-13 | 2021-02-22 | Incyte Corp | Cyclopropylamines as lsd1 inhibitors |
| US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
| US9695167B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors |
| US9695180B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
| US9695168B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors |
| MA51438A (fr) | 2015-04-03 | 2021-04-14 | Incyte Corp | Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1 |
| SG10202001219UA (en) | 2015-08-12 | 2020-03-30 | Incyte Corp | Salts of an lsd1 inhibitor |
| CR20180553A (es) | 2016-04-22 | 2019-02-01 | Incyte Corp | Formulaciones de un inhibidor de lsd1 |
| JP7595413B2 (ja) | 2016-11-30 | 2024-12-06 | ケース ウエスタン リザーブ ユニバーシティ | １５－ｐｇｄｈ阻害剤とコルチコステロイドおよび／またはｔｎｆ阻害剤との組み合わせならびにその使用 |
| CA3052466A1 (en) | 2017-02-06 | 2018-08-09 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase activity |
| MX389825B (es) * | 2017-03-31 | 2025-03-20 | Aurigene Discovery Tech Ltd | Compuestos y composiciones para tratar trastornos hematologicos. |
| CN107954977A (zh) * | 2017-12-15 | 2018-04-24 | 上海鼎雅药物化学科技有限公司 | 雷替曲塞中间体的合成方法 |
| WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
| CA3120858A1 (en) | 2018-11-21 | 2020-05-28 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase activity |
| CN116113406B (zh) * | 2020-07-10 | 2025-08-29 | 密歇根大学董事会 | Gas41抑制剂及其使用方法 |
| JP2024516353A (ja) | 2021-04-08 | 2024-04-15 | キュリス，インコーポレイテッド | がんの治療のための併用療法 |
| CN115702156A (zh) * | 2021-04-23 | 2023-02-14 | 南京明德新药研发有限公司 | 吡啶酰胺类化合物 |
| CN116715668A (zh) * | 2022-03-07 | 2023-09-08 | 上海凌达生物医药有限公司 | 一类含氮杂环类细胞周期抑制剂化合物、制备方法和用途 |
| WO2024088192A1 (en) * | 2022-10-26 | 2024-05-02 | Js Innopharm (Suzhou) Ltd. | An aurora a inhibitor for use in treatments of cancers |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7576085B2 (en) * | 2002-09-23 | 2009-08-18 | Schering Corporation | Imidazopyrazines as cyclin dependent kinase inhibitors |
| US6919341B2 (en) * | 2002-09-23 | 2005-07-19 | Schering Corporation | Imidazopyrazines as cyclin dependent kinase inhibitors |
| WO2006053121A2 (en) * | 2004-11-10 | 2006-05-18 | Cgi Pharmaceuticals, Inc. | Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity |
| EP1945644A2 (en) * | 2005-11-10 | 2008-07-23 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
-
2008
- 2008-06-11 CA CA2690557A patent/CA2690557A1/en not_active Abandoned
- 2008-06-11 WO PCT/US2008/007295 patent/WO2008156614A2/en not_active Ceased
- 2008-06-11 CN CN200880101960A patent/CN101772500A/zh active Pending
- 2008-06-11 AR ARP080102481A patent/AR066958A1/es not_active Application Discontinuation
- 2008-06-11 MX MX2009013729A patent/MX2009013729A/es not_active Application Discontinuation
- 2008-06-11 PE PE2008001001A patent/PE20090365A1/es not_active Application Discontinuation
- 2008-06-11 EP EP08768351A patent/EP2170892A2/en not_active Withdrawn
- 2008-06-11 JP JP2010512177A patent/JP2010529195A/ja not_active Withdrawn
- 2008-06-12 CL CL2008001745A patent/CL2008001745A1/es unknown
- 2008-06-12 TW TW097121942A patent/TW200911811A/zh unknown
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014501496A (ja) * | 2010-10-20 | 2014-01-23 | ユニヴェルシテ ボルドー セガラン | 消化管間質腫瘍における臨床転帰のシグネチャーおよび消化管間質腫瘍の治療の方法 |
| JP2023523962A (ja) * | 2020-04-29 | 2023-06-08 | エフ． ホフマン－ラ ロシュ アーゲー | 抗菌８－フェニルアミノ－３－（ピラゾール－４－イル）イミダゾ［１，２－ａ］ピラジン誘導体 |
| JP7771084B2 (ja) | 2020-04-29 | 2025-11-17 | エフ． ホフマン－ラ ロシュ アーゲー | 抗菌８－フェニルアミノ－３－（ピラゾール－４－イル）イミダゾ［１，２－ａ］ピラジン誘導体 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008156614A2 (en) | 2008-12-24 |
| CL2008001745A1 (es) | 2008-12-05 |
| MX2009013729A (es) | 2010-01-25 |
| EP2170892A2 (en) | 2010-04-07 |
| CN101772500A (zh) | 2010-07-07 |
| CA2690557A1 (en) | 2008-12-24 |
| AR066958A1 (es) | 2009-09-23 |
| PE20090365A1 (es) | 2009-04-04 |
| TW200911811A (en) | 2009-03-16 |
| WO2008156614A3 (en) | 2009-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5031760B2 (ja) | プロテインキナーゼインヒビターとしてのイミダゾピラジン | |
| JP2010529195A (ja) | プロテインキナーゼの阻害剤としてのイミダゾピラジン | |
| JP5520325B2 (ja) | プロテインキナーゼを阻害するためのピラゾロ［１，５−ａ］ピリミジン誘導体の使用およびプロテインキナーゼを阻害する方法 | |
| JP5052518B2 (ja) | プロテインキナーゼインヒビターとしてのピラゾロピリミジン | |
| JP5109109B2 (ja) | サイクリン依存性キナーゼ阻害剤としての新規イミダゾピラジン | |
| JP5241834B2 (ja) | プロテインキナーゼ阻害剤としての複素環アミド化合物 | |
| JP5063700B2 (ja) | アニリノピペラジン誘導体およびアニリノピペラジン誘導体を使用する方法 | |
| JP2009539840A (ja) | プロテインキナーゼ阻害剤としてのイミダゾピラジン | |
| JP2009515882A (ja) | プロテインキナーゼを阻害するための方法 | |
| WO2009097233A9 (en) | Imidazopyrazines as protein kinase inhibitors | |
| JP2010509328A (ja) | プロテインキナーゼの阻害剤としてのイミダゾピラジン | |
| JP2009511478A (ja) | プロテインキナーゼインヒビターとしてのピラゾロピリミジン | |
| JP2009511484A (ja) | プロテインキナーゼインヒビターとしてのピラゾロピリミジン | |
| AU2006302435B2 (en) | Use of pyrazolo [1 , 5 -a] pyrimidine derivatives for inhibiting protein kinases methods for inhibiting protein kinases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A072 | Dismissal of procedure [no reply to invitation to correct request for examination] |
Free format text: JAPANESE INTERMEDIATE CODE: A073 Effective date: 20110617 |
|
| A300 | Application deemed to be withdrawn because no request for examination was validly filed |
Free format text: JAPANESE INTERMEDIATE CODE: A300 Effective date: 20110906 |